Fermented canola and seaweed feed and food products - prebiotics, probiotics and bioactives

Fermented canola and seaweed feed and food products - prebiotics, probiotics and bioactives

International Conference on Industrial Biotechnology and Bioprocessing
August 16-17, 2018 | Copenhagen, Denmark

Soren Kjaerulff

FermBiotics, Denmark

Abstract:

FermBiotics and Fermentationexperts have developed several fermented plant and seaweed products for pigs, poultry and human health. The products consist of prebiotics, probiotics and bioactives from the fermented plant and seaweed material. We have demonstrated very good in vitro anti-microbial and anti-inflammatory activities of the fermented material. A pig trial shows that fermented feed called EP100i containing fermented canola can replace zinc oxide in pig’s feed. The European Commission (EC) has voted in favour of a ban on the veterinary use of zinc oxide in feed. An additional pig trial showed a high (58%) reduction of LDL-cholesterol in pigs given 4 % EP100i feed compared with normal feed. We have demonstrated positive gut microbiome modulation in several animal models. FermBiotics will in collaboration with Silkeborg Hospital, Denmark in the EU project Macro Cascade run a randomized double-blinded matched cross trial using a dose of 5 g fermented canola and seaweed material. The clinical trial will be performed in N=80 human patients with mild-moderate state of Inflammatory Bowel Disease (IBD) and/or Spondyloarthropathy (SPA) including both gender.

Biography:

Søren Kjærulff is currently CEO of Fermbiotics and CTO of Fermentationexperts. He is responsible for development of fermented plant and macroalgae food and feed products with microbiome modulatory activity and for introducing the product to the market, investigate and develop its functionality, identify the regulatory requirements, as well as go-to-market strategies. He was the former senior director of biopharmaceuticals R&D at Novozymes and responsible for anti-microbial and anti-inflammatory peptides and albumin half-life extension of peptide drugs. He also served as the former vice president of R&D at Pantheco and Santaris Pharma.

E-mail: sk@fermbiotics.com

PDF HTML